期刊
NUCLEAR MEDICINE AND BIOLOGY
卷 31, 期 3, 页码 345-355出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.nucmedbio.2003.10.008
关键词
glioma; brain tumors; monoclonal antibodies; tenascin; radiotherapy
资金
- NCI NIH HHS [CA42324, CA11898] Funding Source: Medline
- NINDS NIH HHS [NS20023] Funding Source: Medline
- PHS HHS [95ER62021] Funding Source: Medline
We have obtained encouraging responses in recent Phase I studies evaluating I-131-labeled human/murine chimeric 81C6 anti-tenascin monoclonal antibody (ch81C6) administered into surgically-created tumor resection cavities in brain tumor patients. However, because the blood clearance is slow, hematologic toxicity has been higher than seen with murine 81C6 (mu81C6). In the current study, a series of paired-label experiments were performed in athymic mice bearing subcutaneous D-245 MG human glioma xenografts to compare the biodistribution of the fragment ch81C6 F(ab')(2) labeled using lodogen to a) intact ch81C6, b) mu81C6, and c) ch81C6 F(ab')(2) labeled using N-succinimidyl 3-[I-131]iodobenzoate. Tumor retention of radioiodine activity for the F(ab')(2) fragment was comparable to that for intact ch81C6 for the first 24 h and to that for mu81C6 for the first 48 h; as expected, blood and other normal tissue levels declined faster for ch81C6 F(ab')(2). Radiation dosimetry calculations suggest that I-131-labeled ch81C6 F(ab')(2) may warrant further evaluation as a targeted radiotherapeutic for the treatment of brain tumors. (C) 2004 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据